This article is more than 5 years old. Information may no longer be current.
Medicare, insurance beneficiaries have improved access to uveal melanoma test
Click Here to Manage Email Alerts
Three important access milestones for DecisionDx-UM have been reached, Castle Biosciences announced in a press release.
DecisionDx-UM, a prognostic test for uveal melanoma, has been issued a final local coverage determination from Palmetto GBA, effective July 10, 2017, improving access to the test for Medicare patients.
The test has also obtained a positive coverage policy with 14 Blue Cross Blue Shield insurance plans and a positive coverage policy with Aetna as of July 1, 2017, the release said.
“These coverage decisions mark important progress toward broadening patient access to the DecisionDx-UM test. We are pleased that 57 million Medicare recipients and more than 58 million insurance members affiliated with the BCBS and Aetna commercial plans will now have improved access to the DecisionDx-UM test, which is standard of care for those who are diagnosed with uveal melanoma,” Derek Maetzold, president and CEO of Castle Biosciences, said in the release.